What’s Akcea Therapeutics, Inc. (AKCA) Upside After Today’s Significant Increase?

March 14, 2018 - By Linda Rogers

The stock of Akcea Therapeutics, Inc. (NASDAQ:AKCA) is a huge mover today! The stock increased 3.56% or $0.7 during the last trading session, reaching $20.34. About 286,889 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 7 months positive chart setup for the $1.36 billion company. It was reported on Mar, 14 by Barchart.com. We have $22.17 PT which if reached, will make NASDAQ:AKCA worth $121.95M more.

Analysts await Akcea Therapeutics, Inc. (NASDAQ:AKCA) to report earnings on May, 28. After $-0.26 actual earnings per share reported by Akcea Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 30.77 % negative EPS growth.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Coverage

Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 5 analyst reports since August 8, 2017 according to SRatingsIntel. The stock of Akcea Therapeutics, Inc. (NASDAQ:AKCA) has “Buy” rating given on Tuesday, August 8 by Stifel Nicolaus. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, October 31. The stock has “Buy” rating by BMO Capital Markets on Tuesday, August 8. Stifel Nicolaus maintained Akcea Therapeutics, Inc. (NASDAQ:AKCA) rating on Tuesday, November 7. Stifel Nicolaus has “Buy” rating and $20.0 target.

More important recent Akcea Therapeutics, Inc. (NASDAQ:AKCA) news were published by: Globenewswire.com which released: “Akcea Therapeutics to Present at Upcoming Investor Conferences” on March 06, 2018, also Streetinsider.com published article titled: “Akcea Therapeutics (AKCA) Announces FDA Panel Meeting to Review Volanesorsen …”, Globenewswire.com published: “Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End …” on February 26, 2018. More interesting news about Akcea Therapeutics, Inc. (NASDAQ:AKCA) was released by: Globenewswire.com and their article: “Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College …” with publication date: March 12, 2018.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.36 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.